Resistance to Proteasome Inhibitors in Cancer

Molecular Mechanisms and Strategies to Overcome Resistance

Nonfiction, Health & Well Being, Medical, Specialties, Oncology, Medical Science, Pharmacology
Cover of the book Resistance to Proteasome Inhibitors in Cancer by , Springer International Publishing
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9783319067520
Publisher: Springer International Publishing Publication: September 16, 2014
Imprint: Springer Language: English
Author:
ISBN: 9783319067520
Publisher: Springer International Publishing
Publication: September 16, 2014
Imprint: Springer
Language: English

The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume.

This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume.

This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.

More books from Springer International Publishing

Cover of the book Information and Software Technologies by
Cover of the book Frontiers in Pen and Touch by
Cover of the book Water Resources of Jordan by
Cover of the book Riemannian Computing in Computer Vision by
Cover of the book Headache in Children and Adolescents by
Cover of the book Protections of Tenure and Academic Freedom in the United States by
Cover of the book Remote Sensing Time Series by
Cover of the book Annual Update in Intensive Care and Emergency Medicine 2018 by
Cover of the book Neutron Scattering and Other Nuclear Techniques for Hydrogen in Materials by
Cover of the book Contemporary Influences on International Business in Latin America by
Cover of the book The Strauss-Krüger Correspondence by
Cover of the book Multifocal Intraocular Lenses by
Cover of the book Umberto Eco, The Da Vinci Code, and the Intellectual in the Age of Popular Culture by
Cover of the book Open Problems in the Geometry and Analysis of Banach Spaces by
Cover of the book Dependable Software Engineering. Theories, Tools, and Applications by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy